Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials.
It has collaboration and license agreements with F.
Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University.
The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 26 | -3.58 Decreased by -288.42% | -1.05 Decreased by -240.95% |
| Nov 3, 25 | -0.13 Decreased by -138.24% | -0.70 Increased by +81.39% |
| Aug 6, 25 | 2.02 Increased by +2.79 K% | 0.70 Increased by +188.57% |
| Apr 29, 25 | -3.42 Decreased by -1.02 K% | -0.65 Decreased by -426.64% |
| Feb 26, 25 | 1.90 Increased by +304.26% | 2.06 Decreased by -7.78% |
| Nov 6, 24 | 0.34 Increased by +173.91% | -0.13 Increased by +361.54% |
| Aug 7, 24 | 0.07 Increased by +125.93% | 0.01 Increased by +600.00% |
| May 1, 24 | 0.37 Increased by +106.31% | -0.07 Increased by +628.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 442.93 M Decreased by -32.73% | -282.85 M Decreased by -277.84% | Decreased by -63.86% Decreased by -364.35% |
| Sep 30, 25 | 399.36 M Decreased by -14.52% | -179.95 M Decreased by -635.38% | Decreased by -45.06% Decreased by -726.30% |
| Jun 30, 25 | 611.09 M Increased by +68.38% | 196.89 M Increased by +2.95 K% | Increased by +32.22% Increased by +1.71 K% |
| Mar 31, 25 | 744.86 M Increased by +80.15% | -447.51 M Decreased by -1.34 K% | Decreased by -60.08% Decreased by -787.75% |
| Dec 31, 24 | 658.41 M Increased by +65.94% | 159.05 M Increased by +248.37% | Increased by +24.16% Increased by +109.94% |
| Sep 30, 24 | 467.17 M Increased by +40.79% | 33.61 M Increased by +182.10% | Increased by +7.19% Increased by +158.32% |
| Jun 30, 24 | 362.93 M Increased by +38.93% | 6.46 M Increased by +126.98% | Increased by +1.78% Increased by +119.42% |
| Mar 31, 24 | 413.46 M Increased by +63.10% | 36.12 M Increased by +106.99% | Increased by +8.74% Increased by +104.29% |